Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% EBIT per Share is $3.72 as of Sep. 2025. The stock has 2 warning signs investors should review. Among 1,172 Biotechnology companies, Windtree Therapeutics ranks better than 95.65% on this metric.
Windtree Therapeutics's EBIT per Share for the
three
months ended in Sep. 2025 was $-1.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $3.72.
During the past 3 years, the average EBIT per Share Growth Rate was 75.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Windtree Therapeutics's EBIT per Share or its related term are showing as below:
WINT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 75.5 Med: 75.5 Max: 75.5
Current: 75.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Windtree Therapeutics was 75.50% per year. The lowest was 75.50% per year. And the median was 75.50% per year.
WINT's 3-Year EBIT Growth Rate is ranked better than 95.65% of 1172
companies
in the Biotechnology industry
Industry Median: 15.5
vs WINT: 75.50
Windtree Therapeutics (OTCPK:WINT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Windtree Therapeutics EBIT per Share Related Terms
Windtree Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a EBIT per Share of $3.72 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Windtree Therapeutics and its competitors. According to the industry distribution chart, Windtree Therapeutics ranks #51 out of 1172 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Windtree Therapeutics' EBIT per Share too high?
Windtree Therapeutics' current EBIT per Share is $3.72. The Biotechnology industry median EBIT per Share is 15.50. Windtree Therapeutics' value of $3.72 is 76% below this industry median. Based on the distribution chart, Windtree Therapeutics ranks #51 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Windtree Therapeutics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #51 out of 1172 companies for EBIT per Share. This places Windtree Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. Windtree Therapeutics' value of $3.72 is 76% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windtree Therapeutics's current EBIT per Share of $3.72 is 76% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Windtree Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current EBIT per Share is $3.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current EBIT per Share of $3.72. The current EBIT per Share is $3.72 and 76% below the Biotechnology industry median of 15.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current EBIT per Share is $3.72 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
